Key Development The European Commission has approved Novo Nordisk's once-daily oral Wegovy for chronic weight management, making it the first... Read more
Category: Uncategorized
WHO LEADS THE CDC MATTERS MORE THAN EVER FOR U.S. PUBLIC HEALTH
Key Development Leadership transitions within major public health agencies rarely attract widespread attention. However, the nomination process for the next... Read more
ELI LILLY’S PSYCHEDELIC STRATEGY SIGNALS A NEW PHASE IN NEUROSCIENCE INVESTMENT
Key Development Eli Lilly is reportedly nearing an agreement to acquire AtaiBeckley, a biotechnology company developing psychedelic-based therapies for mental... Read more
WHEN SURGICAL BACKLOGS BECOME A HEALTH SYSTEM WARNING SIGNAL
Key Development One of Vietnam's largest oncology centers is experiencing an unprecedented surgical backlog, with more than 1,000 cancer patients... Read more
VIETNAM MEDI-PHARM EXPO 2026 POSITIONS VIETNAM AS AN EMERGING HUB FOR HEALTHCARE INNOVATION
Key Development Vietnam Medi-Pharm Expo 2026 is bringing together more than 300 healthcare and pharmaceutical companies from over 15 countries... Read more
NEKO HEALTH’S $700 MILLION FUNDING SIGNALS A NEW ERA FOR AI-DRIVEN PREVENTIVE HEALTHCARE
Key Development Sweden-based health technology company Neko Health has secured $700 million in Series C financing as it prepares to... Read more
THE INDUSTRIALIZATION OF CELL THERAPY IS RESHAPING THE FUTURE OF BIOMANUFACTURING
Key Development The cell therapy industry is entering a new stage of maturity, where manufacturing capability is becoming just as... Read more
FDA APPROVAL IS NO LONGER THE FINISH LINE: HOW COMMERCIAL READINESS IS REDEFINING BIOTECH SUCCESS
The U.S. Food and Drug Administration (FDA) has approved Revtorpyk (gedatolisib), developed by Celcuity, for certain patients with advanced or... Read more
BEYOND THE $1.5 BILLION DEAL: WHY ASTRAZENECA’S LATEST CHINA BET SIGNALS A NEW ERA IN GLOBAL ONCOLOGY
AstraZeneca has entered into an exclusive global licensing agreement with China's Dizal Pharmaceutical for Zegfrovy (sunvozertinib), an oral targeted therapy... Read more









